Vertex Pharmaceuticals Inc (VRTX : NASDAQ)
Common Stock
$503.25
USD
-2.39 (-0.47%)
Last updated: 2026-10-08
Follow VRTX
VRTX
Vertex Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-0.47%
1 Week
-0.69%
1 Month
-4.85%
YTD
+11.31%
Key Statistics
Market Cap
$128.16B
52W High
$560.25
52W Low
$402.58
P/E Ratio
29.45
50 Day MA
$519.19
200 Day MA
$474.12
Beta
0.28
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/8/2026 | $503.14 | $507.87 | $498.90 | $503.25 | $503.25 | 1,487,881 |
| 10/7/2026 | $504.07 | $511.50 | $503.94 | $505.64 | $505.64 | 806,524 |
| 10/6/2026 | $505.00 | $507.41 | $496.33 | $502.31 | $502.31 | 775,000 |
| 10/5/2026 | $504.78 | $506.01 | $496.15 | $503.50 | $503.50 | 902,477 |
| 10/2/2026 | $509.50 | $509.50 | $499.95 | $504.73 | $504.73 | 939,600 |
| 10/1/2026 | $522.39 | $523.52 | $505.27 | $506.74 | $506.74 | 1,194,400 |
| 9/30/2026 | $525.26 | $529.72 | $522.74 | $522.81 | $522.81 | 1,146,000 |
| 9/29/2026 | $522.22 | $529.46 | $519.25 | $526.73 | $526.73 | 688,800 |
| 9/28/2026 | $524.27 | $529.89 | $521.16 | $527.67 | $527.67 | 823,500 |
| 9/25/2026 | $522.55 | $527.69 | $518.92 | $526.19 | $526.19 | 756,200 |
Analyst Price Targets
Based on 32 analysts covering VRTX · as of Oct 5, 2026
Wall Street analysts forecast VRTX stock price to rise 13.5% over the next 12 months.
Consensus
Buy4.34 / 5.00
Avg. Target
US$571.39
+13.5% Upside
Current Price
US$503.25
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VRTX's historical volatility
30-Day Vol
18.5%
Annualized
90-Day Vol
27.4%
Annualized
Trend (90d)
+22.4%
Annualized drift
90d Mean
US$545.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$516.87 | US$484.88 – US$550.97 |
| 60 trading days | US$530.86 | US$484.99 – US$581.06 |
| 90 trading days | US$545.22 | US$488.10 – US$609.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Financials
- Revenue (TTM)
- $12.59B
- EBITDA
- $5.10B
- Profit Margin
- 35.00%
- ROE (TTM)
- 23.54%
- EPS (Diluted)
- 17.17
- Book Value
- 79.92
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About VRTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| FLYE | Fly-E Group, Inc. Common Stock | $2.32 | +82.68% |
| JZ | Jianzhi Education Technology Group Company Limited American Depositary Shares | $0.83 | +77.52% |
| EURKR | Eureka Acquisition Corp Right | $0.44 | +62.87% |
| AIXI | XIAO-I Corporation | $1.93 | +46.21% |
| PCRX | Pacira BioSciences, Inc. | $36.39 | +44.40% |
| QNME | Quanome Technologies, Inc. | $0.83 | +43.28% |
| OLB | OLB Group Inc | $0.55 | +41.86% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +33.33% |
VRTX.US news timeline
11 articles covering VRTX.US, most recent first
Latest